More than 76,000 people in the US are diagnosed each year with renal cell carcinoma (RCC). Increased approval of oral therapies and recent guideline updates both elevate the pharmacy team’s important role to support patients in managing their treatment. Learn about pathophysiology, assessments, diagnosis, and treatment algorithm updates for patients with RCC.

Upon successful completion of this knowledge-based CPE course, pharmacy technicians should be able to:
1. List the signs and symptoms of renal cell carcinoma
2. Identify commonly used medications for the treatment of renal cell carcinoma
3. Compare and contrast common adverse reactions of medications used to treat renal cell carcinoma
4. Discuss the role of the pharmacy technician in the patient journey for persons with renal cell carcinoma

Kelly Brunk, PharmD, BCOP
Clinical Pharmacist
The University of Kansas Health System

Kelly Brunk does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course.

Note: Off-label use will be discussed in this course.

This course is included in our Pharmacy Technician Subscription Services. To get more courses like this sent to you every month, sign-up for a CE Subscription Service!  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Initial Release Date: October 1, 2021
Planned Expiration Date: October 1, 2024